Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
11 studies found for:    golimumab, ulcerative colitis
Show Display Options
Rank Status Study
1 Recruiting A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis
Condition: Colitis, Ulcerative
Intervention: Drug: Golimumab
2 Recruiting Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab
Condition: Ulcerative Colitis
Intervention: Drug: Golimumab
3 Recruiting Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)
Condition: Ulcerative Colitis
Interventions: Drug: Golimumab Prefilled Syringe;   Drug: Golimumab Smartject™ Device
4 Recruiting Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention:
5 Recruiting Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)
Condition: Ulcerative Colitis
Intervention: Drug: Golimumab
6 Recruiting A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.
Condition: Colitis, Ulcerative
Interventions: Drug: Golimumab;   Other: Placebo
7 Terminated
Has Results
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
Condition: Colitis, Ulcerative
Interventions: Other: Placebo;   Drug: Golimumab 1 mg per kg;   Drug: Golimumab 2 mg per kg;   Drug: Golimumab 4 mg per kg
8 Completed
Has Results
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
Condition: Colitis, Ulcerative
Interventions: Biological: Placebo;   Biological: Golimumab 100 mg;   Biological: Golimumab 200 mg;   Biological: Golimumab 400 mg;   Biological: Golimumab 50 mg
9 Recruiting A Study to Evaluate the Accuracy of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Condition: Colitis, Ulcerative
Intervention: Biological: Golimumab
10 Active, not recruiting
Has Results
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
Condition: Colitis, Ulcerative
Interventions: Biological: Placebo;   Biological: Golimumab 50 mg;   Biological: Golimumab 100 mg;   Biological: Golimumab 200 mg
11 Recruiting A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
Condition: Hepatosplenic T-Cell Lymphoma
Intervention: Biological: Collection of samples

Indicates status has not been verified in more than two years